Moreover, the expression levels of PTX3, TNFAIP6, and TNFAIP8L2 and the genetic alterations of TNFAIP1, TNFAIP6, and STEAP4 greatly impact the clinical outcome of HNC patients, likely by regulating the PI3K-Akt, Ras or other signalling pathways or by regulating tumour immune status. The gene discussed is AKT1; the disease is neoplasm.